ABSTRACT
Prostate cancer is frequently encountered among men and it is also a health problem with high diagnostic and treatment costs. Studies showed that appropriate risk stratification can improve oncologic outcomes, therefore the importance of prostate cancer imaging gains huge role in the management of these patients. In this review, we tried to summarize the role of both conventional imaging and state-of-the-art imaging modalities such as functional magnetic resonance imaging and molecular hybrid imaging in the primary and secondary staging of prostate cancer patients.
References
1Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-386.
2Gandaglia G, Fossati N, Stabile A, et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol 2017;72:289-292.
3Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study Eur Urol 2014;65:1058-1066.
4Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in clinically non-organ-confined prostate cancer. Curr Urol Rep 2014;15:455.
5Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618-629.
6Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990.
7de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 2016;70:233-245.
8Morlacco A, Sharma V, Viers BR, et al. The incremental role of magnetic resoncance imaging for prostate cancer staging before radical prostatectomy. Eur Urol 2017;71:701-704.
9Lebacle C, Roudot-Thoraval F, Moktefi A, et al. Integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy. World J Urol 2017;35:1409-1415.
10Schiavina R, Bianchi L, Borghesi M, et al. MRI displays the prostatic-cancer anatomy and improves the bundles management before robot-assisted radical prostatectomy. J. Endourol 2017;32:315-321.
11Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer -major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:245-253.
12Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent update 2013. Eur Urol 2014;65:124-137.
13Thurtle D, Hsu RC, Chetan M, et al. Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer. Br J Cancer 2016;115:1285.
14Hovels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol 2008;63:387-395.
15Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 2017;73:178-211.
16Briganti A, Abdollah F, Nini A, et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 2012;61:1132-1138.
17Gabriele D, Collura D, Oderda M, et al. Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World J Urol 2016;34:517-523.
18Outwater EK, Montilla-Soler JL. Imaging of prostate carcinoma. Cancer Control 2013;20:161–176.
19Kundra V, Silverman PM, Matin SF, et al. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. Am J Roentgenol 2007;189:830-844.
20Pasoglou V, Larbi A, Collette L, et al. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all in one” imaging approach? Prostate 2014;74:469-477.
21Messiou C, Cook G, DeSouza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br. J. Cancer 2009;101:1225-1232.
22Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 2014;43:1503.
23Briganti A, Passoni N, Ferrari M, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010;57:551-558.
24Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171:2122–2127.
25Derlin T, Eiber M, Schwaiger M, Bengel FM. Re: Lars Budäus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016;69:393-6. Eur Urol 2016;70:e37-38.
26Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high- risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2013;63:1040-1048.
27van Leeuwen PJ, Emmett L, Ho B, et al. Prospective evaluation of 68Gallium- prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 2017;119:209-215.
28Gupta M, Choudhury PS, Hazarika D, Rawal S. A Comparative Study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience. World J Nucl Med 2017;16:186-191.
29Schiavina R, Bianchi L, Borghesi M, Sabbatini R, Brunocilla E. Toward the future of the functional imaging of advanced prostate cancer. Eur Urol Focus 2017;3:240-242.
30Panebianco V, Barchetti F, Grompone MD, et al. Magnetic resonance imaging for localization of prostate cancer in the setting of biochemical recurrence. Urol Oncol Semin Orig Investig 2016;34:303-310.
31Maurer T, Eiber M, Fanti S, Budäus L, Panebianco V. Imaging for prostate cancer recurrence. Eur Urol Focus 2016;2:139-150.
32Woodrum DA, Kawashima A, Gorny KR, Mynderse LA. Prostate cancer: state of the art imaging and focal treatment. Clin Radiol 2016;72:1-15.
33Alfarone A, Panebianco V, Schillaci O, et al. Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer. Crit Rev Oncol Hematol 2012;84:109-121.
34Sciarra A, Panebianco V, Salciccia S, et al. Role of dynamic contrastenhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54:589.
35Cha D, Kim CK, Park SY, Park JJ, Park BK. Evaluation of suspected soft tissue lesion in the prostate bed after radical prostatectomy using 3T multiparametric magnetic resonance imaging. Magn Reson Imaging 2015;33:407.
36Sugimura K, Carrington BM, Quivey JM, Hricak H. Postirradiation changes in the pelvis: assessment with MR imaging. Radiology 1990;175:805-813.
37Abd-Alazeez M, Ramachandran N, Dikaios N, et al. Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images. Prostate Cancer Prostatic Dis 2015;18:128.
38Halabi S, Kelly WK, Ma H. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 2016;34:1652–1659.
39Nakajima K, Edenbrandt L, Mizokami A. Bone scan index: a new biomarker of bone metastasis in patients with prostate cancer. Int J Urol 2017;24:668-673.
40Evangelista L, Briganti A, Fanti S, et al. New clinical indications for (18)F/ (11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 2016;70:161-175.
41Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68 Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56:668-674.
